Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface.
[4] Ocriplasmin can degrade various structural proteins, including laminin and fibronectin, which are localized in the vitreoretinal surface.
Ocriplasmin is currently being studied in clinical trials and data indicate that it is able to induce posterior vitreous detachment in vitreomacular adhesion patients.
The FDA stated that the adverse effects may not cause long-term harm, but that conclusion could not be definitively made.
ThromboGenics received a $123 million-plus payment, when ocriplasmin gained approved in the Europe Union; this occurred in March 2013.